CADTH Invites Patient Advocacy Group and Registered Clinician Input on: Axicabtagene Ciloleucel (TBD) for Diffuse large B-cell lymphoma (DLBCL)[Due 23-Nov-2018]
This is to notify stakeholders that CADTH is anticipating that a submission will be made for Axicabtagene Ciloleucel (TBD) for diffuse large B-cell lymphoma (DLBCL).
Patient groups that have registered with CADTH are invited to provide input by using the Patient Input Template for CADTH CAR T-Cell Therapy Reviews.
Clinicians and clinician groups that have registered with CADTH are invited to provide input using the Clinician Input Template for Axicabtagene Ciloleucel for Diffuse large B-cell lymphoma (DLBCL).
The targeted deadline for receiving stakeholder input on Axicabtagene Ciloleucel (TBD) for diffuse large B-cell lymphoma (DLBCL) is November 23, 2018 by 5:00 p.m. Eastern Time. This submission is now open for input and patient group and clinician submissions can be made through the CADTH website.
Patient groups and clinicians who have not yet registered with CADTH and would like to provide input are invited to visit CADTH Registration for details on registration.
CADTH is an independent, not-for-profit organization responsible for providing Canada’s health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs and medical devices in our health care system. CADTH receives funding from Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
Learn more at: www.cadth.ca.